A Study to Learn How Receiving Chemotherapy for Osteosarcoma Affects the Male Reproductive System

Full Title

ALTE16C1-Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma (CIRB)

Purpose

Significant progress has been made in curing childhood cancers over the past 20 years. With this success has come the awareness that childhood cancer treatment may lead to complications in some patients. Some chemotherapy drugs are known to cause fertility problems (difficulty fathering children) in male patients. Doctors want to know if cisplatin with or without ifosfamide (common treatments for osteosarcoma) causes similar problems later in life for patients initially treated for osteosarcoma as adolescents and young adults. That is the goal of this study.

Participants in this study include male osteosarcoma survivors who will be asked to:

  • Complete a questionnaire about their health, history of medication and drug use, history of fathering children, possible environmental exposures, and other factors that may affect the ability to have children.
  • Provide a saliva sample to be analyzed for genes that may affect the impact of osteosarcoma treatment on fertility.
  • Provide a semen specimen for a fertility assessment.
  • Give a blood sample to be evaluated for levels of hormones such as testosterone, as another measure of fertility.

The results of these assessments will be compared with patients’ medical records, including prior osteosarcoma treatment, to evaluate the effects of the therapy on their fertility.

Eligibility

Patients in this study include men ages 18-50 who were previously treated for osteosarcoma with cisplatin, with or without ifosfamide, two or more years before entering the study.

For more information about this study, please contact Dr. Danielle Friedman at 212-639-7376.

Protocol

18-551

Co-Investigators